[go: up one dir, main page]

MXPA02012054A - Compuestos de dicetopiracina tetraciclica como inhibidores de la fosfodiesterasa v. - Google Patents

Compuestos de dicetopiracina tetraciclica como inhibidores de la fosfodiesterasa v.

Info

Publication number
MXPA02012054A
MXPA02012054A MXPA02012054A MXPA02012054A MXPA02012054A MX PA02012054 A MXPA02012054 A MX PA02012054A MX PA02012054 A MXPA02012054 A MX PA02012054A MX PA02012054 A MXPA02012054 A MX PA02012054A MX PA02012054 A MXPA02012054 A MX PA02012054A
Authority
MX
Mexico
Prior art keywords
pdev inhibitors
diketopiperazine compounds
compounds
tetracyclic
tetracyclic diketopiperazine
Prior art date
Application number
MXPA02012054A
Other languages
English (en)
Inventor
W Orme Mark
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of MXPA02012054A publication Critical patent/MXPA02012054A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de una estructura general de formula (I) y sales y solvatos de los mismos, y el uso de los compuestos como inhibidores de PDES. (ver formula).
MXPA02012054A 2000-06-08 2001-05-15 Compuestos de dicetopiracina tetraciclica como inhibidores de la fosfodiesterasa v. MXPA02012054A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21032400P 2000-06-08 2000-06-08
PCT/US2001/015937 WO2001094347A1 (en) 2000-06-08 2001-05-15 Tetracyclic diketopiperazine compounds as pdev inhibitors

Publications (1)

Publication Number Publication Date
MXPA02012054A true MXPA02012054A (es) 2003-06-06

Family

ID=22782443

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012054A MXPA02012054A (es) 2000-06-08 2001-05-15 Compuestos de dicetopiracina tetraciclica como inhibidores de la fosfodiesterasa v.

Country Status (7)

Country Link
US (1) US20030153575A1 (es)
EP (1) EP1289990A1 (es)
JP (1) JP2004533402A (es)
AU (1) AU2001268065A1 (es)
CA (1) CA2411010A1 (es)
MX (1) MXPA02012054A (es)
WO (1) WO2001094347A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101632669B (zh) 2000-08-04 2011-05-18 Dmi生物科学公司 二酮基哌嗪和包含它们的组合物的使用方法
EP1383765B1 (en) 2001-04-25 2006-12-13 Lilly Icos LLC Carboline derivatives as inhibitors of phosphodiesterase 5 (PDE5) for the treatment of cardiovascular diseases and erectile dysfunction
JP4339679B2 (ja) * 2001-06-21 2009-10-07 リリー アイコス リミテッド ライアビリティ カンパニー Ｐｄｅ５阻害剤としてのカルボリン誘導体
JP4674317B2 (ja) * 2002-10-02 2011-04-20 ディエムアイ アクイジション コーポレイション 疾病の判定および監視
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
EP2517722B1 (en) 2003-05-15 2016-03-02 Ampio Pharmaceuticals, Inc. Synthesis of diketopiperazines
JP2007518788A (ja) 2004-01-22 2007-07-12 ファイザー・インク バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
US8217047B2 (en) 2008-05-27 2012-07-10 Dmi Acquisition Corp. Therapeutic methods and compounds
WO2012033792A2 (en) 2010-09-07 2012-03-15 Dmi Acquisition Corp. Treatment of diseases
PH12014500686A1 (en) 2011-10-10 2020-12-18 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
PH12014500685B1 (en) 2011-10-10 2018-10-03 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
CA2846394A1 (en) 2011-10-28 2013-05-02 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
SG11201506267XA (en) 2013-03-15 2015-09-29 Ampio Pharmaceuticals Inc Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
CN106810554B (zh) * 2017-01-14 2019-02-15 山东罗欣药业集团恒欣药业有限公司 一种他达拉非化合物的制备方法
CN106977516B (zh) * 2017-03-02 2019-06-18 山东裕欣药业有限公司 一种他达拉非的制备方法
CN112041301A (zh) 2018-02-28 2020-12-04 费罗治疗公司 具有铁死亡诱导活性的化合物及其使用方法
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2178477A1 (en) * 1993-12-07 1995-06-15 Louis J. Theodore Pretargeting methods and compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
CA2365782A1 (en) * 1999-04-30 2000-11-09 William E. Pullman Treatment of female arousal disorder
IL135817A0 (en) * 1999-04-30 2001-05-20 Lilly Icos Llc Phosphodiesterase enzyme inhibitors and their use in pharmaceutical articles

Also Published As

Publication number Publication date
CA2411010A1 (en) 2001-12-13
US20030153575A1 (en) 2003-08-14
AU2001268065A1 (en) 2001-12-17
JP2004533402A (ja) 2004-11-04
WO2001094347A8 (en) 2002-04-04
EP1289990A1 (en) 2003-03-12
WO2001094347A1 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
MXPA02012054A (es) Compuestos de dicetopiracina tetraciclica como inhibidores de la fosfodiesterasa v.
AU2002246728A1 (en) Carboline derivatives
GB0124933D0 (en) Chemical compounds
AU2002249890A1 (en) Carboline derivatives
AU2001266575A1 (en) Chemical compounds
MXPA03002911A (es) Compuestos quimicos.
YU39803A (sh) Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
TW200508199A (en) Novel compound
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU2002213419A1 (en) Condensed pyridoindole derivatives
AP2002002466A0 (en) 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS.
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
MXPA02012472A (es) Compuestos quimicos.
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
AP2001002045A0 (en) FKBP inhibitors.
MXPA03011167A (es) Derivados de carbolina utiles como ihibidores de pdev.
MXPA03000887A (es) Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa.
MXPA05011855A (es) 1,2-diarilimidazoles utiles como inhibidores de ciclooxigenasa.
ATE360422T1 (de) Tetrazyklische verbindungen als pde5-inhibitoren
SI0937075T1 (en) New Imidazo- and Oxazolopyridines as Phosphodiesterase Inhibitors.
IL169334A0 (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors
AP2001002047A0 (en) Isoquinoliness as urokinase inhibitors.